knowledge -WSS

knowledge

author：explore 2025-10-02 10:45:57 - browse：9

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Sage's campaign to raise awareness of postpartum depression hits a nerve

WSS

An Ebola outbreak presents a new mystery involving children

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Choosing scientific sides in the fight against Alzheimer's

Judge rejects Trump's counterclaim against E. Jean Carroll

Wegovy cuts risk of cardiovascular events by 20%, study finds

hotspot

knowledge

focus

Jerome Adams on the need for new antivirals for Covid

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Affirmative action in medical school literally saved lives

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Readout Newsletter: Biotech news today

Sports medicine is finally prioritizing gender equality

CZI to create biohub to build anti

Medical records are filled with copy

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

focus

FTX founder Sam Bankman

Wegovy cuts risk of cardiovascular events by 20%, study finds

STAT Summit: Ending the crisis of Black deaths in the U.S.

An Ebola outbreak presents a new mystery involving children

Astronauts get first look at the spacecraft that will fly them around the moon

More regulation could be coming for drug ads

Wikipedia

Wikipedia

hotspot

Wikipedia